Strong PhII data in triglyceride reduction attracts partners to Essentialis
This article was originally published in Scrip
Executive Summary
Essentialis Inc. is in discussions with partners and potential acquirers as its moves into Phase III clinical trials for diazoxide choline controlled-release tablets, or DCCR, a drug that may cause dramatic reductions in triglyceride levels for high-risk patients who already are taking cholesterol-lowering medications.
You may also be interested in...
Capina, Essentialis Merger To Create Rare Disease Firm
The combined company would advance a diazoxide choline controlled-release daily pill for treating patients with Prader-Willi syndrome through pivotal Phase II/III clinical trialing.
Kite Readies A Second CAR-T For Filing As CD19 Competition Grows
The Gilead subsidiary presented updated data at ASH for its first CD19-targeting CAR-T Yescarta and pivotal results for KTE-X19, which it plans to submit for US FDA approval in mantle cell lymphoma this year.
Bristol’s CAR-T Strategy Comes Into Focus With Two Near-Term Filings
In its first ASH since acquiring Celgene and with competitors coming, Bristol presented pivotal results for liso-cel (JCAR017) that support a year-end US FDA submission as bb2121 nears a first-half of 2020 filing.
Need a specific report? 1000+ reports available
Buy Reports